%20copy.svg)
VOXZOGO needed a robust go-to-market launch strategy and digital ecosystem to educate families and drive patient initiation following FDA approval.
As the first FDA-approved treatment for Achondroplasia, VOXZOGO faced a critical moment: educating families, physicians, and caregivers at launch. We built an end-to-end strategy—starting with segmentation and messaging development, all the way through to UX, design, and development of both the disease education site and brand.com. Our integrated GTM approach drove meaningful awareness and helped more than 1,000 patients begin their VOXZOGO journeys in the first year alone.
